Pharmacological perspective: glycyrrhizin may be an efficacious therapeutic agent for COVID-19

dc.creatorLuo, Pan
dc.creatorLiu, Dong
dc.creatorLi, Juan
dc.date.accessioned2020-07-31T20:10:52Z
dc.date.accessioned2022-09-23T18:13:07Z
dc.date.available2020-07-31T20:10:52Z
dc.date.available2022-09-23T18:13:07Z
dc.date.created2020-07-31T20:10:52Z
dc.identifier0924-8579
dc.identifierhttps://doi.org/10.1016/j.ijantimicag.2020.105995
dc.identifierhttp://hdl.handle.net/20.500.12010/11493
dc.identifierhttps://doi.org/10.1016/j.ijantimicag.2020.105995
dc.identifier.urihttp://repositorioslatinoamericanos.uchile.cl/handle/2250/3497521
dc.description.abstractCoronavirus disease 2019 (COVID-19) caused by the previously unknown pathogen, severe acute respiratory syndrome-related coronavirus-2 (SARS-CoV-2) is now a global pandemic. There are no vaccines or specific treatments against this new virus; therefore, there is an urgent need to advance novel therapeutic interventions for COVID-19. Glycyrrhizin is a triterpene saponin with various biological functions and pharmacological effects. This brief article discusses the therapeutic potential of glycyrrhizin for the treatment of COVID-19 from the perspective of its pharmacological action, including binding angiotensinconverting enzyme II (ACE2), downregulating proinflammatory cytokines, inhibiting the accumulation of intracellular reactive oxygen species (ROS), inhibiting thrombin, inhibiting the hyperproduction of airway exudates, and inducing endogenous interferon.
dc.publisherScience Direct
dc.rightsinfo:eu-repo/semantics/openAccess
dc.sourcereponame:Expeditio Repositorio Institucional UJTL
dc.sourceinstname:Universidad de Bogotá Jorge Tadeo Lozano
dc.subjectCOVID-19
dc.subjectSARS-COV-2
dc.subjectGlycyrrhizin
dc.titlePharmacological perspective: glycyrrhizin may be an efficacious therapeutic agent for COVID-19


Este ítem pertenece a la siguiente institución